SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

iSERA Lifesciences Ltd (534920)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 534920 NSE: IT - Software | Small Cap | iSERA Lifesciences Share Price

₹94.17 4.48 (4.99%)

As on 05-Jun'26 09:09

iSERA Lifesciences Ltd (534920)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 534920 NSE: IT - Software | Small Cap | iSERA Lifesciences Share Price

₹94.17 4.48 (4.99%)

As on 05-Jun'26 09:09

Key Metrics
Valuation Multiples
Market Cap
₹75 Cr.
Current Price
₹94.2
52-Week Low / High
₹2 / 90
TTM EPS
₹0.3
TTM Sales
₹1.4 Cr.
Book Value per Share
₹9.8
P/E Ratio
290.08
Industry PE
22.2
Price to Book (P/B)
9.14
Higher than its 5-year historical median
Price to Sales (P/S)
55.66
EV/EBITDA
220.23
Higher than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
0.00%
Underperforms industry median
Return on Capital Employed (ROCE)
18.82%
Outperforms industry median
Return on Assets (ROA)
17.28%
Operating Profit Margin
52.4%
Net Profit Margin
52.41%
Gross Profit Margin
52.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
58.63%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹8.4 Cr.
Face Value
₹10
All Time Low / High
₹0.53 / 152.00

iSERA Lifesciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is iSERA Lifesciences Ltd a good quality company?
iSERA Lifesciences Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does iSERA Lifesciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of iSERA Lifesciences Ltd vs industry peers?
iSERA Lifesciences Ltd revenue CAGR is -33.84%, compared to the industry median CAGR of 2.48%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of iSERA Lifesciences Ltd?
Promoters hold 58.63% of the iSERA Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of iSERA Lifesciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 30.9% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
iSERA Lifesciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -100%3.5%4.1%2.9%-2.4%-4.6%-11.1%-5,149.5%0%18.8%-
Value Creation
Index
-8.1-0.8-0.7-0.8-1.2NA-1.8NANA0.3-

Growth Parameters

Sales 25.521.428.912.32.100000.31
Sales YoY Gr.--16.2%35.4%-57.5%-82.7%-100%NANANANA-
Adj EPS -4.400.1-0-0.5-0.30-4.7-3.95.40.3
YoY Gr.-NA400%-140%NANANANANANA-
BVPS (₹) 0.60.60.70.60.1-0.10-4.9-8.5-3.89.8
Adj Net
Profit
-3.700-0-0.4-0.3-0.1-0.1-0.10.10
Cash Flow from Ops. 0.8-0.6-0.50.314.5-0.3-0.1-0.1-1.4-
Debt/CF from Ops. 7.6-10.9-14.621.96.80.50-1-3-1.2-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales -39.7%-33.8%NANA
Adj EPS NANANANA
BVPS-222.9%-296.7%NANA
Share Price 37.2% 162.9% 305.7% 4538.9%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-54.817.3-2.9-130-8044.1190.9185.159.7-88.810.4
Op. Profit
Mgn %
1.42.11.62.6-2.5000052.421.4
Net Profit
Mgn %
-14.600.1-0.1-19.6000052.419.2
Debt to
Equity
12.213.513.714.258.4-190-1.1-0.9-16.40.2
Working Cap
Days
1321981784041,82000001,09284
Cash Conv.
Cycle
-872-938-5,645-10,718-4,3910000-16071

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales25.5021.3628.9212.302.1300000.27
Operating Expenses > + 25.1420.9128.4611.982.190.190.110.120.100.13
Manufacturing Costs0.030.050.010000000
Material Costs0000000000
Employee Cost 0.420.550.130.060.060.0400.020.020.02
Other Costs > 24.6920.3228.3211.912.130.140.110.100.080.10
Operating Profit > 0.360.450.460.32-0.05-0.19-0.11-0.12-0.100.14
Operating Profit Margin (%) 1.4%2.1%1.6%2.6%-2.5%----52.4%
Other Income > + 000000.080000
Exceptional Items > -12.61000000000
Interest > 0.160.200.270.230.220.020000
Depreciation > 0.080.210.150.080.120.100000
Profit Before Tax > -12.490.040.040.01-0.40-0.22-0.11-0.11-0.100.14
Tax > 0.050.030.010.020.0200000
Profit After Tax -12.5400.04-0.02-0.42-0.22-0.11-0.11-0.100.14
PAT Margin (%) -49.2%0.0%0.1%-0.1%-19.6%----52.4%
Adjusted EPS (₹)-15.00.00.1-0.0-0.5-0.30.0-4.7-3.95.4
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of iSERA Lifesciences - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 0.500.510.550.530.11-0.11-0.31-0.12-0.22-0.10
Share Capital 10.6010.6010.6010.6010.6010.6000.300.320.32
Reserves -10.10-10.09-10.05-10.07-10.49-10.71-0.31-0.42-0.54-0.42
Debt +6.156.837.497.536.562.0200.130.181.61
Long Term Debt4.545.305.745.946.562.0200.130.181.61
Short Term Debt1.611.531.751.59000000
Minority Interest0000000000
Trade Payables2.873.186.173.172.861.81000.030.02
Others Liabilities 1.742.392.020.950.940.780.310.040.050.02
Total Liabilities 11.2612.9116.2212.1810.474.5000.050.051.55

Fixed Assets

Net Fixed Assets +0.480.440.450.750.620.430000
Gross Block1.091.251.411.791.791.701.70000
Accumulated Depreciation0.610.820.961.051.171.271.70000
CWIP 0000000000
Investments 0000000000
Inventories0000000000
Trade Receivables8.5810.2214.1010.028.582.910000.31
Cash Equivalents 0.030.010.010.010.0100000.02
Others Assets 2.172.241.671.401.271.1500.050.051.22
Total Assets 11.2612.9116.2212.1810.474.5000.050.051.55

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 0.81-0.63-0.510.340.974.45-0.30-0.12-0.06-1.40
PBT -12.5400.040.01-0.40-0.22-0.11-0.11-0.100.14
Adjustment 12.700.170.140.110.140.100000
Changes in Working Capital 0.65-0.81-0.690.251.254.56-0.19-0.010.04-1.52
Tax Paid 00-0.01-0.02-0.02-0000-0.02
Cash Flow From Investing Activity + -0.40-0.16-0.16-0.3800.100000
Capex -0.40-0.16-0.16-0.3800.100000
Net Investments 0000000000
Others 0000000000
Cash Flow From Financing Activity + -0.420.770.660.04-0.97-4.550.300.130.061.42
Net Proceeds from Shares 0000000.30000
Net Proceeds from Borrowing 0-0.03000000.130.061.42
Interest Paid 0000000000
Dividend Paid 0000000000
Others -0.420.790.660.04-0.97-4.550000
Net Cash Flow -0.01-0.02-0.0100-0.0100-00.02

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-185.160.977.27-2.91-129.99N/AN/AN/AN/AN/A
ROCE (%)-99.983.454.072.94-2.4N/AN/AN/AN/AN/A
Asset Turnover Ratio1.61.771.990.870.1900000.33
PAT to CFO Conversion(x)N/AN/A-12.75N/AN/AN/AN/AN/AN/A-10
Working Capital Days
Receivable Days102.50160.60153.503581,591.400000430.70
Inventory Days0000000000
Payable Days0000000000

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.00100.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

iSERA Lifesciences Ltd FAQs

The current trading price of iSERA Lifesciences on 05-Jun-2026 09:09 is ₹94.17.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of iSERA Lifesciences stood at ₹75.42 Cr

The latest P/E ratio of iSERA Lifesciences as of 04-Jun-2026 is 290.1.

The latest P/B ratio of iSERA Lifesciences as of 04-Jun-2026 is 9.14.

The 52-week high of iSERA Lifesciences is ₹89.69 and the 52-week low is ₹1.50.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of iSERA Lifesciences is ₹1.36 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that iSERA Lifesciences Ltd is a below average quality company.

The key valuation ratios of iSERA Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of iSERA Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About iSERA Lifesciences Ltd

No data to display
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×